“ÌìÐн¡£¬£¬£¬£¬£¬£¬£¬¾ý×ÓÒÔ×ÔÇ¿²»Ï¢¡£¡£¡£¡£¡£¡£¡£¡£ÕóÊÆÀ¤£¬£¬£¬£¬£¬£¬£¬¾ý×ÓÒÔºñµÂÔØÎï¡£¡£¡£¡£¡£¡£¡£¡£”

    µ±¾ºÈüÆÀίÔÚÏÖ³¡Ðû²¼Ñï×Ó½­Ò©Òµ¼¯ÍŹãÖݺ£ÈðÒ©ÒµÓÐÏÞ¹«Ë¾ÌìÐн¡QCС×é»ñµÃÒ»µÈ½±µÄ˲¼ä£¬£¬£¬£¬£¬£¬£¬½ÒÏþÈËÔøÊËÐãÓë¶ÓÓÑÃÇÀÎÀÎÓµ±§£¬£¬£¬£¬£¬£¬£¬ÀáË®¶á¿ô¶ø³ö¡£¡£¡£¡£¡£¡£¡£¡£

    ÕâÊÇ×·Çó׿Խ¡¢¾«µñϸ×ÁÖ®¹¤½³¾«ÉñµÄʤÀû¡£¡£¡£¡£¡£¡£¡£¡£

    ÔÚGT100-D¶³¸É»ú×öÕæ¿Õ×ß©ÂÊʱ£¬£¬£¬£¬£¬£¬£¬¸ÚλְԱ·¢Ã÷ÊýÖµÁè¼ÝÄڿرê×¼£¬£¬£¬£¬£¬£¬£¬Í¨¹ý3´ÎÖØ¸´ÊÔÑ飬£¬£¬£¬£¬£¬£¬Õæ¿Õ×ß©ÂÊÕÕ¾ÉÁè¼ÝÄڿرê×¼¡£¡£¡£¡£¡£¡£¡£¡£¶³¸É»úÕæ¿Õ×ß©Âʹý¸ß½«µ¼ÖÂÕæ¿Õ¶È²»¿É¼á³Ö£¬£¬£¬£¬£¬£¬£¬´Ó¶øÊ¹²úÆ·Éý»ª¸ÉÔïͨµÀÊÜ×裬£¬£¬£¬£¬£¬£¬½«Ó°Ïì²úÆ·ÖÊÁ¿£¬£¬£¬£¬£¬£¬£¬ÇÒ¿ÉÄÜʹ²úÆ·ÎÞ¾úÐÔÎÞ·¨»ñµÃ°ü¹Ü¡£¡£¡£¡£¡£¡£¡£¡£½â¾öÕâ¸öÎÊÌâÆÈÔÚü½Þ¡£¡£¡£¡£¡£¡£¡£¡£

    ÒÑÒ»Á¬°ËÄêÕ¶»ñÌìÏÂÒ½Ò©ÐÐÒµQCЧ¹ûÒ»µÈ½±µÄÌìÐн¡QCС×é¾öÒé¹¥ÏÝÕâ¸öÄѹØ¡£¡£¡£¡£¡£¡£¡£¡£

    ÒªÈ·¶¨×îºóÒòËØÊǼ«Æä¼èÄѵÄ£¬£¬£¬£¬£¬£¬£¬ÐèÒª´ÓÈË¡¢»ú¡¢ÁÏ¡¢·¨¡¢»·£¬£¬£¬£¬£¬£¬£¬ÕûÌåµØË¼Ë÷¿ÉÄܵÄ×ß©µã£¬£¬£¬£¬£¬£¬£¬Ò»¸öϸ΢µÄ»·½Úδ˼Á¿µ½£¬£¬£¬£¬£¬£¬£¬¶¼ÓпÉÄܵ¼Ö¹¥¹ØÊ§°Ü¡£¡£¡£¡£¡£¡£¡£¡£

    Àú³Ì²¢²»Ë³Ë죬£¬£¬£¬£¬£¬£¬ÔÚÅŲé¸÷¸ö·§ÃÅ¿ª¹ØµÄʱ¼ä£¬£¬£¬£¬£¬£¬£¬187¸ö·§ÃŵÃÒ»¸ö¸ö²ðжÏÂÀ´£¬£¬£¬£¬£¬£¬£¬Ó÷Ŵó¾µ×ÐϸÊӲ졣¡£¡£¡£¡£¡£¡£¡£

    “±ØÐèÔÚ¹¤³Ìʦµ½À´Ö®Ç°°ÑÕâ187¸ö·§ÃŶ¼ÅŲéÒ»±é¡£¡£¡£¡£¡£¡£¡£¡£”Áõ±òÓÃË»ÑÆµÄÉùÒô¼á¾öÏÂÁî¡£¡£¡£¡£¡£¡£¡£¡£´Ëʱ£¬£¬£¬£¬£¬£¬£¬Áõ±òÒѾ­Á½¸ö¶àÔÂûÓÐÐÝÏ¢ÁË£¬£¬£¬£¬£¬£¬£¬Ò»Á¬¸ßÇ¿¶ÈµÄÊÂÇ飬£¬£¬£¬£¬£¬£¬ÑʺíÑס¢ÖØÉËΣº¦Ð©Ñ¹¿åÁËËûÏûÊݵÄÉíÌ壬£¬£¬£¬£¬£¬£¬ÑÛ¾¦Àï³äÂúѪ˿£¬£¬£¬£¬£¬£¬£¬¿´ÁËÁîÈËÐÄÌÛ¡£¡£¡£¡£¡£¡£¡£¡£

    “ÊÇ£¬£¬£¬£¬£¬£¬£¬ÎÒÃǰü¹ÜÍê³ÉʹÃü£¡”ÉîÒ¹µÄ¶³¸É»ú·¿À£¬£¬£¬£¬£¬£¬ÇÄȻһÏÂ×Ó±»Í»ÆÆÁË£¬£¬£¬£¬£¬£¬£¬¸÷È˶þ»°²»Ëµ£¬£¬£¬£¬£¬£¬£¬ÓÖóÆÖ¾Ã¦ÂµÆðÀ´¡£¡£¡£¡£¡£¡£¡£¡£

    ¾­ÓÉÍŽáЭ×÷£¬£¬£¬£¬£¬£¬£¬ËûÃÇÌáǰһÌìÍê³ÉÁËʹÃü£¬£¬£¬£¬£¬£¬£¬×îÖÕÕÒµ½Ôì³É¶³¸É»úÕæ¿Õ×ß©Âʹý´óµÄ»ù´¡Ôµ¹ÊÔ­ÓÉ£ºÀäÚåҺѹ¸×µÄ²»Ðâ¸ÖÖá·â´¦ÓнϴóµÄ¹ÎºÛ£¬£¬£¬£¬£¬£¬£¬Ôì³É×ß©¡£¡£¡£¡£¡£¡£¡£¡£

    “¹¤½³¾«Éñ”´ÙʹËûÃǶÔËù×öµÄÊÂÇéÏñ“Ç¿ÆÈÖ¢”Ò»Ñù²»·Å¹ýÈκÎÒ»¸öϸ½Ú¡£¡£¡£¡£¡£¡£¡£¡£ËûÃǵÄרעÓë¼á³Ö»ñµÃÁ˻ر¨£¬£¬£¬£¬£¬£¬£¬Ìæ»»Öá·â¼Üºó£¬£¬£¬£¬£¬£¬£¬¶³¸É»úÕæ¿Õ×ß©ÂÊ´Ó0.041mbar·L/S½µÖÁ0.011mbar·L/S£¬£¬£¬£¬£¬£¬£¬µÖ´ïÔ¤ÆÚµÄ¹¥¹ØÄ¿µÄ¡£¡£¡£¡£¡£¡£¡£¡£

    ¡¶×¯×Ó¡·ÔÆ“¼¼½øºõµÀ”£¬£¬£¬£¬£¬£¬£¬“¼¼”¾ÍÊÇ“¹¤½³¾«Éñ”£¬£¬£¬£¬£¬£¬£¬¾ÍÊǶԱ¾Ö°ÊÂÇé½üºõÇ¿ÆÈµÄרע¡¢¼á³Ö¡£¡£¡£¡£¡£¡£¡£¡£Ê±´úÕÙ»½“¹¤½³¾«Éñ”£¬£¬£¬£¬£¬£¬£¬ÐÂʱÆÚµÄÖÆÒ©È˸üÓ¦½«“¹¤½³¾«Éñ”¼ùÐÐÓÚÖÊÁ¿ÖÎÀí£¬£¬£¬£¬£¬£¬£¬½«“¹¤½³¾«Éñ”ÈÚÈëQCÔ˶¯ÖУ¬£¬£¬£¬£¬£¬£¬Íƶ¯ÖйúÖÆÒ©ÒµÒÙÁ¢ÓÚÌìÏÂÖÆÒ©Ö®ÁÖ¡£¡£¡£¡£¡£¡£¡£¡£

http://epaper.cnpharm.com/zgyyb/html/2017-04/11/content_564877.htm?div=-1